Fierce Pharma
DECEMBER 18, 2023
Following a string of approvals in the United States and beyond, Vertex Pharmaceuticals continues to build out its manufacturing network for the world’s first CRISPR-based gene therapy, Casgevy.
MedCity News
DECEMBER 18, 2023
Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
DECEMBER 18, 2023
On a mission to grow in oncology, GSK has more positive data to report in endometrial cancer. | GSK has more positive data to report in endometrial cancer as the company's PD-1/PARP combination turned in a trial win. The combination could represent a threat to a rival therapy at AstraZeneca.
European Pharmaceutical Review
DECEMBER 18, 2023
Findings from a small Phase II clinical trial indicate that psilocybin, a hallucinogenic chemical found in certain mushrooms of the genus Psiloybe , may benefit individuals with cancer and major depression. The open-label trial involved 30 adults with cancer and major depression and was conducted by Sunstone Therapies in Rockville, Maryland. The participants each received a single 25mg dose of synthesised psilocybin, a one-to-one session with a therapist and group therapy support.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
DECEMBER 18, 2023
Bristol Myers Squibb’s PD-1/LAG3 combo Opdualag has more than proved its worth in melanoma since its first-in-class approval in 2022. | The company opted to cut the phase 3 Relativity-123 study after an analysis found that the trial was unlikely to achieve its primary endpoints in microsatellite-stable patients with metastatic colorectal cancer.
PharmExec
DECEMBER 18, 2023
In the coming year, efficiency and automation will take center stage to maximize constrained resources but balancing sensible financial management with strategic investments will be vital.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
DECEMBER 18, 2023
Last week, the ONC announced that TEFCA had finally gone live. This followed years of the ONC heralding the project’s potential to boost interoperability and increase patients’ access to their healthcare data. However, former ONC Chief Don Rucker believes that TEFCA is built on an archaic data exchange protocol that will prevent the initiative from being useful.
Fierce Pharma
DECEMBER 18, 2023
The FDA has signed off on Astellas and Pfizer’s Padcev in combination with Merck’s Keytruda as a first-line treatment for bladder cancer.
European Pharmaceutical Review
DECEMBER 18, 2023
The Novo Nordisk Foundation has committed up to DKK 1.8 billion ($260 million) to establish a state-of-the-art research and vaccine development initiative in Denmark. Developed in partnership with the University of Copenhagen and Denmark’s Statens Serum Institut , the Foundation says this the first vaccines initiative globally to focus solely on understanding how to generate immunity in the airway itself.
pharmaphorum
DECEMBER 18, 2023
Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended by the EMA’s human medicines committee.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
DECEMBER 18, 2023
Applications for registered nurse and advanced practice registered nurse licensure too often contribute to this stigma and prevent nurses struggling with mental health issues from getting needed help.
PharmaVoice
DECEMBER 18, 2023
Advancements in cloud and AI technology will transform clinical trial efficiency and engagement.
MedCity News
DECEMBER 18, 2023
Value-based care depends on keeping a total population of patients healthier and less in need of higher-cost services. To do so, organizations must be able to predict costs in advance, better understand patient risks, and manage the cost of services. Corporate healthcare is set up to do just that.
European Pharmaceutical Review
DECEMBER 18, 2023
At the beginning of this year, EPR reported on the potential blockbuster pharmaceutical drugs to watch in 2023. Since then, EPR has covered developments for several of the therapies highlighted in the report. This includes the National Institute for Health and Care Excellence (NICE)’s recommendation of the first treatment for Parkinson’s disease, Produodopa (foslevodopa–foscarbidopa).
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
DECEMBER 18, 2023
Nearly half of physicians are equally excited and concerned about the use of AI in their field, according to a new AMA survey. Those who felt optimistic about AI cited reduced administrative burden as the number one benefit they’re seeking. Patient privacy and the impact to the patient-physician relationship were the most common reasons physicians cited for having reservations about AI.
PharmExec
DECEMBER 18, 2023
Drug companies face new hurdles in a rapidly changing marketplace. How do they finance new drug development amid the uncertainty?
MedCity News
DECEMBER 18, 2023
Informed decision-making is crucial to operational efficiency, which fundamentally impacts the patient experience, but how do you facilitate it?
Pharmaceutical Technology
DECEMBER 18, 2023
Following US and UK approvals, the EMA’s CHMP has recommended conditional approval for Casgevy, with a decision expected in Q1 2024.
MedCity News
DECEMBER 18, 2023
Despite achieving its Phase 3 study’s main goal, the results for Point Biopharma’s therapy are short of what Novartis radiopharmaceutical Pluvicto achieved in a similarly designed clinical trial. Nevertheless, the data readout should clear the way for Eli Lilly to complete its $1.4 billion acquisition of Point.
pharmaphorum
DECEMBER 18, 2023
Eisai files for approval in Japan for FGFR inhibitor tasurgratinib as a treatment for biliary tract cancers with FGFR2 gene fusions
MedCity News
DECEMBER 18, 2023
HHS announced a new care model that aims to provide mothers with Medicaid coverage with more personalized maternal health care. This includes access to doulas and midwives and screening for health-related social needs.
pharmaphorum
DECEMBER 18, 2023
RUBY Part 2 trial of GSK's PD-1 inhibitor Jemperli and PARP inhibitor Zejula could open up wider use in first-line endometrial cancer
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
MedCity News
DECEMBER 18, 2023
Season Health has secured a $7 million investment from Inception Health and Ziegler Link-age Fund. The financing will be used to develop and scale its food-as-medicine programs, including for diabetes and high-risk pregnancies.
PharmaTimes
DECEMBER 18, 2023
MCI patients had 25% lower levels of serotonin compared to healthy patients Researchers from Johns Hopkins Medicine have suggested that serotonin loss in parts of the brain may play a role in cognitive decline in the early stages of Alzheimer’s disease (AD). Published in the Journal of Alzheimer’s Disease , the study was supported by other contributing scientists from the Johns Hopkins University School of Medicine and the Johns Hopkins Bloomberg School of Public Health.
pharmaphorum
DECEMBER 18, 2023
Illumina will divest cancer detection company Grail after losing an appeal in an antitrust court case in the US
Pharmaceutical Technology
DECEMBER 18, 2023
The Novo Nordisk Foundation has invested Dkr1.8bn in the initiative to develop vaccines for various airborne infection diseases.
PharmaTimes
DECEMBER 18, 2023
MCI patients had 25% lower levels of serotonin compared to healthy patients - News - PharmaTimes
Pharmaceutical Commerce
DECEMBER 18, 2023
Cloud-based service to address verification of saleable returns under the latest DSCSA regulations.
PharmaTimes
DECEMBER 18, 2023
Earlier diagnosis could increase patient survival rates by five years or more - News - PharmaTimes
Salesforce
DECEMBER 18, 2023
Think about what could happen if you don’t have a good handle on your field service assets. Without a proper process in place, you risk operational inefficiencies, increased costs, and a decline in overall performance. You might even jeopardize the safety of your employees, contractors , and customers. Enter asset service management, the process of effectively managing and maintaining physical assets in field service.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
286 
Let's personalize your content